Vaxcyte Inc. (PCVX): Price and Financial Metrics


Vaxcyte Inc. (PCVX): $22.01

-1.11 (-4.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PCVX Stock Price Chart Interactive Chart >

Price chart for PCVX

PCVX Price/Volume Stats

Current price $22.01 52-week high $58.47
Prev. close $23.12 52-week low $15.51
Day low $21.67 Volume 182,400
Day high $23.17 Avg. volume 336,336
50-day MA $19.97 Dividend yield N/A
200-day MA $30.31 Market Cap 1.13B

Vaxcyte Inc. (PCVX) Company Bio


Vaxcyte, Inc. engages in development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Francisco, CA.


PCVX Latest News Stream


Event/Time News Detail
Loading, please wait...

PCVX Latest Social Stream


Loading social stream, please wait...

View Full PCVX Social Stream

Latest PCVX News From Around the Web

Below are the latest news stories about Vaxcyte Inc that investors may wish to consider to help them evaluate PCVX as an investment opportunity.

Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update

FOSTER CITY, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. “Over the past few months, we have made good progress as we advance VAX-24, our 24-valent pneumococcal conjugate vaccine (PCV), toward the anticipated submission of the Investigational New Drug (IND) application in order to generate clinical proof-of-concept data,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “While we remain laser-focused on delivering on our VAX-24 mi...

Yahoo | May 11, 2021

Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease

VAX-24 is a 24-Valent Broad-Spectrum Pneumococcal Conjugate Vaccine Leveraging Vaxcyte’s Technology PlatformFOSTER CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the publication of preclinical data supporting the potential of VAX-24, its lead vaccine candidate, in the journal Vaccine. VAX-24 is an investigational 24-valent pneumococcal conjugate vaccine (PCV) designed to prevent invasive pneumococcal disease, which can be most serious for infants, young children, older adults and those with immune deficiencies or certain chronic health condi...

Yahoo | May 10, 2021

Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference

FOSTER CITY, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced that company management will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 1:30 p.m. ET. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About VaxcyteVaxcyte is a next-generation vaccine company seeking to improve global healt...

Yahoo | April 5, 2021

Vaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

FOSTER CITY, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update. “The past year has been transformational for Vaxcyte and I am pleased with the multiple milestones we have achieved on the path to submit our Investigational New Drug (IND) application for VAX-24, our 24-valent pneumococcal conjugate vaccine (PCV), the progress of our other pipeline programs, and the addition of new leadership team members,” said Grant Pickering, Chief Executiv...

Yahoo | March 29, 2021

Vaxcyte Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 29, 2021 / Vaxcyte Inc (NASDAQ:PCVX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 29, 2021 at 4:30 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.

Yahoo | March 29, 2021

Read More 'PCVX' Stories Here

PCVX Price Returns

1-mo 14.40%
3-mo -18.69%
6-mo -32.21%
1-year -15.83%
3-year N/A
5-year N/A
YTD -17.16%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7517 seconds.